hers compounded semaglutide review Hims & Weight Loss (2026) – Forbes Health Hims & Hers Stock Plummets.

In TRIUMPH-4 (obesity + knee OA): nausea 43%, diarrhea 33%, dysesthesia 20.9%

This stands in stark contrast to the ubiquitous expression seen in rodent thyroids

We think this is a big deal. The company plans to seek regulatory approval for orforglipron for weight management by the end of this year and for the treatment of type 2 diabetes in 2026

Thirst perception in response to beverage pictures was higher for patients with primary polydipsia than for controls, and lower for patients on dulaglutide versus placebo, but functional activity was similar among groups and treatments

It also has a Better Business Bureau profile with mixed reviews and has faced regulatory scrutiny, including an FTC warning letter in 2020 regarding unsubstantiated COVID-19 and earnings claims

My sense is 3.5 mg RT = 5 mg of TZ in potency